Dermata Therapeutics regains Nasdaq minimum bid price compliance

Dermata Therapeutics, Inc.

Received Nasdaq non-compliance notice on May 14, 2025 due to bid price below $1.00.
Requested hearing; granted exception until August 14, 2025 to demonstrate compliance.
On August 22, 2025, staff confirmed compliance with Minimum Bid Price Requirement; matter closed.
Common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq Capital Market.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.